(Source: Johnson & Johnson) c5053730-3d54-465c-81d1-a0a6a3d74237.pdf November 16, 2015 Janssen Presents New Data Assessing OLYSIO® (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt --OSIRIS study results presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco-- BEERSE, Belgium--(BUSINESS WIRE)-- Janssen-Cilag International NV (Janssen) today announced the preliminary results from the Phase IIa OSIRIS trial, at the Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. The OSIRIS trial, investigating once daily OLYSIO®...
↧